on HYBRIGENICS (EPA:ALHYG)
Inoviem Scientific and DeepLife: Innovative Collaboration for IBD
On September 24, 2026, the ATON Group announced a major collaboration between its subsidiary Inoviem Scientific and DeepLife, combining expertise in human tissue pharmacology and artificial intelligence. Together, they aim to revolutionize the treatment of inflammatory bowel diseases (IBD), where current therapies often fail to provide lasting remission.
Inoviem uses its human intestinal tissue bank to test therapeutic targets identified by TwinCell, DeepLife's AI platform. This synergy allows for the direct observation of biological mechanisms and the refinement of each hypothesis, thus reinforcing Inoviem's role as a key partner in the validation of new AI-assisted treatments.
With more actionable evidence, this ambitious partnership could guide decisions towards more personalized medicine, providing solutions to contemporary therapeutic challenges.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all HYBRIGENICS news